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Abstract
Background: Although international guidelines encourage urate lowering therapy (ULT) for people who have more
than two attacks of gout, only 30 % of patients are prescribed it and only 40 % of those adhere to the treatment.
The aim was to explore reasons for this through an exploration of patient experience and understanding of ULT
treatment for gout.
Methods: A qualitative study was conducted throughout the United Kingdom. Narrative and semi-structured
video-recorded interviews and thematic analysis were used.
Results: Participants talked about their views and experiences of treatment, and the factors that affected their use
of ULT. The analysis revealed five main themes: 1) knowledge and understanding of gout and its treatment; 2)
resistance to taking medication; 3) uncertainty about when to start ULT; 4) experiences of using ULT; and 5) desire
for information and monitoring.
Conclusion: Patients’ understanding and experiences of gout and ULT are complex and it is important for clinicians
to be aware of these when working with patients. It is also important for clinicians to know that patients’
perceptions and behaviour are not fixed, but can change over time, with changes to their condition, with dialogue
and increased understanding. Patients want this interaction with their clinicians, through “a joint effort over a
period of time”.
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Background
Gout is the most common inflammatory arthropathy, af-
fecting around 2.5 % of United Kingdom residents [1].
Its incidence and prevalence are rising, due to ageing
population, increasing prevalence of metabolic syn-
drome, and lifestyle changes [2]. Gout is also one of the
most treatable rheumatological conditions [3, 4].
Current international guidelines recommend treatment
of acute attacks to reduce pain and inflammation [4–6],
and encourage urate-lowering therapy (ULT) for patients
with two or more acute attacks per year, tophi, renal
stones, radiological damage or impaired renal function
[5, 6]. ULT should be titrated according to serum uric
acid (SUA) levels to achieve and maintain a target of
≤360 μmol/l [5, 6].
Given the high prevalence of gout and availability of
effective treatment, most patients are managed in pri-
mary care [7]. However, the gap between clinical practice
and potential treatment possibilities is large [8]. Long-
term management is often suboptimal, with many pa-
tients living with raised SUA levels and recurrent attacks
[9–14]. Only around 30 % of patients with gout are ever
prescribed ULT [1, 9, 11]. Monitoring and up-titration
of ULT to achieve a target SUA level are not performed
in most patients [10, 14–16].
The literature clearly demonstrates a need for im-
provements in the quality of care for patients with gout,
but the reasons behind current suboptimal management
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are less clear. Patient adherence is one issue, with only
40 % of treated patients adhering to ULT [1]. 70 % of pa-
tients have gaps in ULT – the majority within the first
year of treatment [17]. Previous studies have attributed
the low use of ULT to poor adherence [18], clinical fac-
tors and patients’ financial concerns [19], and adverse
events including ULT induced gout attacks and/or
stigma [20]. In one study only 25 % of patients recently
prescribed ULT were aware it was be used long-term,
and only 12 % knew that it could cause attacks in the
short-term [21].
Clinician concerns about allopurinol hypersensitivity syn-
drome, lack of knowledge about treatment, unfamiliarity
with protocols for titrating ULT, and underprescribing as a
consequence of other recognised barriers such as habit, lack
of motivation or time have been suggested to explain low
rates of treatment with ULT [20]. Improvements in the
knowledge and interest of health professionals, as well as
patients, are urgently needed [1, 7, 22–24].
These quantitative studies do not, however, provide an
in-depth understanding of patients’ experiences and per-
spectives. A small number of gout studies using qualitative
methods have been carried out. One such study found
that patients did not use medication prescribed by their
GP for a number of reasons, including concern about
side-effects, not having experienced an attack for a long
period of time, and lack of understanding of the chronic
nature of the condition [25]. The same study found that
GPs often managed gout as an acute rather than chronic
condition, did not always use guidelines, and tended to as-
sume that patients had a good understanding of the con-
dition. A US based study using focus groups found that
patients were concerned about taking medication, includ-
ing side-effects and long-term issues [26].
However, proposed reasons for ULT underprescrip-
tion, undertreatment and poor adherence have not been
fully explored. In this article we provide evidence for
these reasons, through an exploration of patient experi-
ence and understanding of ULT treatment for gout.
Methods
We used qualitative methods to explore gout patients’
experience and understanding of the condition and its
treatment.
The sample
We interviewed a maximum variation sample [27] of 43
people with gout from across the United Kingdom. We
aimed for a diverse sample, covering experiences and
demographic variables thought to be most important.
The interviews were also intended to be used online as a
resource (healthtalk.org), therefore a geographical spread
of participants was required to provide representation of
experiences in England, Scotland and Wales. A list of
other categories was drawn up covering the types of experi-
ences and demographic variables considered to be import-
ant to patients and clinicians (including current age, age at
diagnosis, sex, years since diagnosis). Inclusion criteria was
a self-reported diagnosis of gout being given from a health-
care practitioner. Patients were recruited through General
Practitioners (GPs), rheumatology clinics, gout support
groups, our expert advisory panel, online advertising and
snowballing through personal contacts. Interviews were
transcribed and analysed concurrently with recruitment
and ongoing recruitment discussed by the research team.
When 43 individuals had been interviewed, it was agreed
that a point of thematic saturation had been reached and
that the sample was sufficient to provide representation of
experiences across all categories.
Table 1 shows the demographic characteristics of our
final sample.
Data collection
An experienced qualitative researcher (JL) conducted
face-to-face semi-structured interviews with 43 partici-
pants in their homes or workplaces. Interviews lasted
between 25 min and two hours. Using a narrative ap-
proach [28], the interviews focused on the oral history of
each person’s experience of gout in order to identify
their concerns, meanings and priorities. The interviewer
used additional questions to prompt reflection on areas
of interest identified through the literature review and/
or advisory group. (Full topic guide available on request).
Using this approach meant that unanticipated areas
could be explored as they arose, thus identifying salient
issues for people with gout.
Data analysis
Following informed consent, interviews were audio or
video recorded depending on participant preference,
transcribed and checked (by JL). JL coded all transcripts
under broad categories, using NVivo 10 (QSR) to assist
with data management. A second researcher (SP)
checked these to identify any additional codes. Analytic
themes relating to specific topics, including long-term
treatment – the focus of this paper – were then devel-
oped further, through discussion with main authors (JR
and JL) [29]. Extracts from interviews and summaries of
other topics are presented on http://healthtalk.org/peo-
ples-experiences/bones-joints/gout/topics.
Results
All participants talked about their views and experiences
of treatment, and factors affecting their use of ULT. We
discuss three anticipated themes (knowledge and under-
standing of gout; experiences of using ULT; information
needs) and two emergent themes (resistance to medica-
tion and uncertainty about starting ULT). Themes are
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presented in an order which reflects a patient’s journey
through the treatment ‘process’. Quotations illustrate typ-
ical responses and the range of experiences, in order to il-
luminate findings. All names are pseudonyms.
1. Knowledge and understanding of gout and its
treatment
Patients’ perceptions and understanding of the
nature of gout influenced their attitude towards
medication. If they did not see it as serious or long-
term they were less likely to take ULT.
“So I know gout’s never going to kill me, right. So I
don’t want to be taking – I don’t want to be rattling
around full of tablets all the time.” (Andrew)
Patients’ understanding of the nature of gout could
change over time, and with experience and
increased knowledge. Adam was explicit about
needing to change the way he thought about gout
in relation to taking medication:
“… it does take a period of adjustment to actually, you
know, ‘I’m going to be doing this for the rest of my life’,
rather than, ‘I’ve got something in the background
which flares up occasionally.”
Increased knowledge of the long-term effects of
gout can move a patient towards a higher likelihood
of taking ULT, illustrated by Vinay and George:
“The doctor said if you don’t take any medication it
will get worse and it can affect your joints, I mean
permanent damage. So I had no choice, I have to take
the medication.” (Vinay)
“Don’t realise when you get it, the effect that its having
on you, and I had some quite severe attacks in my
hands as well as my feet, and that’s left me now with
permanent damage, which I didn’t realise was going to
happen.[…] The pain goes away but the effects of the
attacks of the acid and crystals doesn’t go away, it
remains there.” (George)
2. Resistance to medication
Resistance to medication was a key issue and a major
influence on the likelihood of starting to take ULT.
Patients’ explanations and descriptions of their
medication resistance include the long-term nature
of treatment, sense of identity, dislike of multiple
medications, and desire for self-management.
“If I have a headache I just put up with it [laughs]
whereas I’ve got friends who will swallow any manner
of things, you know, just to avoid a pain of some sort
or another. It’s just the way I am.” (Gail)
“Well I didn’t really want to be on medicine for the
rest of my life, which is what they were suggesting. ”
(Linda)
Some participants, although reluctant to take long-
term medication, were less resistant to short-term
Table 1 Sociodemographic characteristics of sample
Men
(%)
Women
(%)
Total
(%)
(n = 29) (n = 14) (n = 43)
Age group at interview (years):
30–49 4 (14) 3 (21) 7 (16)
50–69 16 (56) 7 (50) 23 (54)
70–89 9 (31) 4 (28) 13 (30)
Ethnicity/Nationality:
White 27 (93) 13 (92) 40 (92)
Asian British 2 (7) 1 (7) 3 (7)
Living arrangements:
Living alone 2 (7) 4 (29) 6 (14)
Living with one other person 20 (69) 6 (43) 26 (60)
Living with more than one other
person
7 (24) 4 (29) 11 (26)
Current work status:
Retired 16 (55) 9 (64) 25 (58)
Full-time work 6 (21) 5 (36) 11 (26)
Part-time work 5 (17) - 5 (12)
Student (higher education) 1 (3) - 1 (2)
Not working for health reasons 1 (3) - 1 (2)
Time since diagnosis (years):
1–5 4 (14) 6 (43) 10 (23)
6–10 2 (7) 4 (29) 6 (14)
11–15 6 (21) 3 (21) 9 (21)
16 or more 17 (59) 1 (7) 18 (42)
Age group at diagnosis (years):
< 30 1 (3) 1 (7) 2 (5)
30–49 19 (66) 4 (29) 23 (53)
50–69 9 (31) 7 (50) 16 (37)
70–89 - 2 (14) 2 (5)
Attacks in past 12 months:
0 10 (3) 4 (29) 14 (33)
1–4 16 (55) 6 (43) 22 (51)
5–9 1 (3) 1 (7) 2 (5)
≥ 10 2 (7) 3 (21) 5 (12)
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treatment, although this form of self-management
also showed aspects of general medication resist-
ance [30, 31], for example, holding tablets ‘in re-
serve’. Maintaining a sense of control was
important for people who wanted to self-manage: in
Gail’s case, she recognised her GP’s support in this:
“I’ve been allowed to be in charge of my own
destiny. To be fair, the doctor has probably
mentioned it before last year […] he hadn’t just left
me for ten years […] But I suppose because of the
way I am, I am so anti taking things that probably
it was a case of me coming round to accepting that
I didn’t have any other options. But, as I say, it’s
always easier to be wiser after the event […] maybe
the medication would have been a better option a
bit sooner, in my experience”.
3. Uncertainty about whether and/or when to start ULT
Participants expressed the idea that a certain
number of gout attacks was acceptable to them.
The acceptable number of attacks varied between
patients, as would be expected, for example,
‘infrequent’ (Joanne), ‘once or twice a year’ (Jason) to
‘every 3 months’ (Simon). Patients who considered a
certain number of attacks acceptable were willing to
self-manage by using medication for acute attacks.
The perceived acceptability of a certain number of
attacks may lead to patients continuing to experi-
ence regular attacks, with the view that their health
professional supports this: indeed the guidelines
recommend a ‘wait and see’ approach. The corollary
of an ‘acceptable’ number of attacks is, of course,
the unacceptable number - that is, the number of
attacks that can precipitate someone into taking
long-term medication, as expressed by Gail:
“I think I read somewhere that the current thinking on
gout is that if you’ve had so many flare-ups – I don’t
know what the number is – that the next step is
medication.”
An increase in the frequency, severity, spread or
impact of attacks was a key factor in moving a
patient towards long-term treatment, even if they
had initially resisted this route.
“Last year, I was getting too many instances and it
was spoiling things, because I have a hobby that I
enjoy and if I’d got gout I couldn’t pursue it until
the gout had gone. And I actually came round to
thinking that I needed to do something more about
it than just trying to manage my diet and dealing
with episodes when they occurred.” (Gail)
4. Patients’ experiences of taking ULT
A key emerging theme was patients’ feeling that the
process of achieving the right dosage was one of
‘trial and error’. Patients reported starting out on a
low dose of allopurinol and then moving up, in
conjunction with SUA level tests, until they reached
optimum dosage. This is in line with current
guidelines and would not be unexpected by
clinicians, but for patients it could be frustrating,
particularly when combined with lack of
explanation, illustrated by Eric:
“Started on 100 mg first and it didn’t improve. And I
was taking the painkilling tablet at the same time. But
when I was taking the 100 mg, your mind thinks […]
‘Why am I taking?’ It gets worse. ‘Why is it getting
worse?’ And it gets frustrating and you go to the
doctors and he ups it to 200 and it still doesn’t go
away and you’re still taking the painkiller. And he ups
it again to 300 and it was still…. It just seems like it
gets a balance and it’s very difficult to understand
why, what’s actually going on.”
Other patients reported that they did not get to
optimum dosage, or reached a point where uric
acid levels were normal, but attacks were
continuing. Some, such as Linda, were not able to
get through initial attack:
“Every time I went on it I had a flare-up of gout, which
they told me to expect, but it was so bad that I just
wanted to get off it. […] They sort of explained, you
know, how the chemicals work, and it’s normal to get a
flare-up but it will go. But I suppose I wasn’t patient
enough to deal with that.” (Linda)
5. Desire for information and monitoring
Most participants knew little about gout before
diagnosis and recalled little written information
from their GP. As described in Section 1,
information is a key factor in patients’ decisions to
start and continue taking ULT. Patients wanted
information on causes of gout, including the role (if
any) of diet, relationship between urate levels and
gout attacks, and the implications of taking
medicine for the rest of their lives. In particular, the
impact of long-term medication was sometimes
seen as being underestimated by the health care
practitioner, illustrated in Adam’s report of his con-
versation with his GP:
“When my attacks became more frequent, I went back
to the GP to ask for a referral back to the
rheumatologist to discuss, you know, ‘Is this the time to
start allopurinol?’ And my GP initially refused to refer
me, he said we didn’t need to - ‘I’ll just put you
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straight on allopurinol’. And I remember, sort of
having a conversation, ‘Well, actually, you know, I’d
like to discuss….’ Because I didn’t like the idea at the
time of going on a medication for the rest of my life.
[…] It is a shift in the way of thinking about the illness
that you’ve got. The prospect of ‘I’ve got to take this for
the rest of my life’, is, it was very difficult to adjust to.
And I said that to my GP, and he matter-of-factly said,
‘Oh, lots of people take tablets for the rest of their life’.
[Adam]
Other patients reported similar feelings:
“I think when you’ve had a diagnosis, it would be
really helpful to sit down quite quickly with a doctor
[…] to actually talk through what your options are…”
(Linda)
“… so I think you need that sort of an approach to try
and help the person understand and get it under
control. So it’s like a joint effort over a period of time,
rather than just a one-off visit after you’ve identified
the problem.” (Henry)
The desire for an ongoing dialogue with a health
care professional, especially while establishing a new
regime, is also reflected in patients’ desire for long-
term monitoring and review of the condition and
treatment.
Discussion
Figure 1 presents our findings in a model, highlighting
factors that influence how likely a person with gout is to
take ULT. The model demonstrates the complexity of,
and interaction between, factors that may explain low
uptake of ULT and suggest what might help a patient to
make an informed choice about medication. The model
includes patient and GP factors: GP factors are the pa-
tients’ understanding and experience of interaction with
their GP, which they reported influencing their beliefs or
behaviour.
Although international guidelines encourage ULT
for people who have more than two attacks of gout
in a year, only 30 % of patients are ever prescribed it
[1, 9, 11]. This study highlights the complexity of fac-
tors influencing the uptake of ULT for long-term
treatment of gout. Using a qualitative approach, with
in-depth interviews, enables an understanding of this
complexity.
In particular, our study provides a detailed explanation
of poor adherence (as reported by patients) but also ex-
plains why patients may resist being prescribed ULT in
the first place. Previous literature has treated prescription
as a GP issue and adherence as a patient issue: our study
suggests the picture is more complex. Patient factors are
involved in the initial decision to prescribe or not pre-
scribe ULT, and GPs can influence whether patients con-
tinue to take prescribed medication.
Patient knowledge and understanding of gout influ-
ences willingness to be initially prescribed ULT. Percep-
tion of gout as intermittent, unwillingness to take
medication in general and desire to self-manage through
diet can all influence this. A great deal of uncertainty
surrounded patients’ knowing when to start taking ULT.
The ‘wait and see’ approach is in line with current guide-
lines. However, patients may not return to the GP after
their first attack, choosing to self-manage.
Importantly, our data demonstrate that some patients
moved from unwillingness to take ULT towards under-
standing its benefits. The key factors in this were a
greater understanding of the nature of gout and/or a
change in symptoms or their impact. This fits with the
findings of a previous questionnaire-based study, which
suggested that adherence to ULT was positively associ-
ated with greater perceived understanding of gout [32].
It also suggests that there is an important opportunity
for GPs to work with patients to change their views and
improve understanding. Patient education helps to
achieve the therapeutic target [24] but information re-
sources have rarely addressed patients’ need for informa-
tion about ULT [19, 33]. While the idea that patients
can change their view may be obvious, there are import-
ant implications for GPs. There is a need to remain open
to dialogue with patients and not rule out offering ULT
again even if initially rejected. In this way the initial rates
of prescription may be increased.
Once ULT has been prescribed, other factors be-
come important in determining whether patients con-
tinue to take it, with one study suggesting 75 % still
taking the starting dose [11]. Our findings provide an
explanation: patients sometimes stopped taking ULT
when an initial attack was precipitated. Others con-
tinued to have attacks while taking ULT but did not
return to their GP, while some did not have their
dose adjusted, remaining on the starting dose. Pa-
tients’ experiences of taking ULT could be frustrat-
ing, when combined with lack of understanding of
the process. These findings add to previous evidence
that few patients understood the role of ULT [21],
indicating a need for health care professionals to be
more explicit in their explanations. Patients wanted
information from, and dialogue with, their health
care professionals, and wanted to have regular moni-
toring once they had chosen to take ULT to reassure
them that the medication was effective and there
were no adverse effects.
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A limitation to this study is that the sample was pre-
dominantly white, of older age and UK based. There
may be different uses of and views on ULT, and cultural
reasons for this, in other populations. All the study par-
ticipants self-reported a diagnosis of gout by a health
care professional. The nature of the study did not allow
us to verify this: previous studies have found this to be
reliable [34].
Using qualitative methods enables us to answer the
question of why ULT is under prescribed and has a
low adherence rate, from a patient’s perspective. We
used trusted methods [25–27] to explore patient ex-
perience. The sample was designed to represent di-
versity of experience, including those who fit the
‘typical’ gout patient profile and those who do not,
rather than be statistically representative; therefore
we do not present the results in frequencies, which
would be misleading. The study is limited to a
United Kingdom (UK) context but has the strength
of being conducted by a multi-disciplinary team of
social scientists and clinicians, who helped to inter-
pret the data.
Conclusions
Effective management of gout requires improvements in
several key areas [35]. Importantly, clinicians need to
‘know how to address illness perceptions and educate
their patients appropriately, so that individualized
management plans can be developed on the basis of
shared decision making’ [[35] p280]. Our study provides
rich evidence on what these perceptions are, how they
influence consequent behaviour and how clinicians can
address this.
Patients’ understanding and experiences of gout and ULT
are complex and it is important for clinicians to be aware
of these. Patients’ perceptions and behaviour are not fixed,
but can change over time, with changes to their condition,
with dialogue and with increased understanding. Patients
want this interaction with their clinicians, summed up by
Henry’s phrase – “a joint effort over a period of time”. Cli-
nicians can support patients’ decision-making with infor-
mation about the role of ULT in long-term treatment,
including expectations and processes within the treatment
pathway. GPs could refer their patients to websites such as
Arthritis Research UK [http://www.arthritisresearchuk.org/
arthritis-information/conditions/gout.aspx] and the health-
talk website section on peoples’ experiences of gout: http://
healthtalkonline.org/peoples-experiences/bones-joints/
gout/topics].
Patients’ experiences, as reported in our study, not
only provide insight into reasons for non-adherence, but
also highlight other factors that influence if, when, and
how ULT is initiated and managed, including the role
that clinicians have played in this process.
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Fig. 1 Factors affecting patients’ use of urate-lowering therapy (ULT) for long-term treatment of gout
Richardson et al. BMC Musculoskeletal Disorders  (2016) 17:249 Page 6 of 8
Acknowledgements
We thank all the people who gave their time to be interviewed. Thank you
to the advisory group: Kelsey M Jordan, Consultant Rheumatologist &
Honorary Senior Lecturer and Trustee of the UK Gout Society; Louise Locock,
Director of Applied Research, Health Experiences Research Group, University
of Oxford; Tom Margham, GP and Lead for Primary Care, Arthritis Research
UK; Carol Rhodes, Patient and Public Involvement Coordinator, Keele
University; Carole Smailes, Interview Participant, Staffordshire.
Funding
Funding was from The National Institute for Health Research School for
Primary Care Research (NIHR SPCR). CDM is funded by an Arthritis Research
UK Clinician Scientist Award. The funders had no role in the design or
conduct of the study; in the collection, analysis, and interpretation of the
data; or in the preparation or approval of the manuscript.
Availability of data and materials
The full data set is not publically available for reasons of confidentiality.
Authors’ contributions
JCR, CDM, JL, ER, SH and SZ conceived and designed the study; all authors
contributed to the design of the semi structured interview schedules. JL
carried out the interviews; JR supervised the analysis of the data; and JR, JL,
CD, SH, SP, SZ and ER drafted the paper. SP acted as research ‘buddy’ for the
project, advising on aspects of Health Talk Online procedure. All authors had
full access to all of the data in the study and can take responsibility for the
integrity of the data and the accuracy of the data analysis. All authors have
read and approved the final version of the manuscript. JR is the guarantor
and affirms that the manuscript is an honest, accurate, and transparent
account of the study being reported; that no important aspects of the study
have been omitted; and that any discrepancies from the study as planned
have been explained.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Informed consent included consent for publication of quotations.
Ethics approval and consent to participate
Ethical approval was given by National Research Ethics Service Committee
South Central Berkshire (12/SC/0495 and 09/H0505/66).
Informed consent was given by all participants.
Author details
1Research Institute for Primary Care and Health Sciences, Keele University,
Keele, Staffs. ST5 5BG, UK. 2Nuffield Department of Primary Care Health
Sciences, University of Oxford, Gibson Building, 1st Floor, Radcliffe
Observatory Quarter, Woodstock Road, Oxford OX2 6GG, UK.
Received: 3 January 2016 Accepted: 2 June 2016
References
1. Kuo C-F, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout
in the UK but continuing suboptimal management: a nationwide
population study. Ann Rheum Dis. 2014;0:1–7.
2. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat
Clin Pract Rheumatol. 2007;3(8):443–9.
3. Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, EULAR
Standing Committee for International Clinical Studies Including
Therapeutics. EULAR evidence based recommendations for gout. Part I:
diagnosis. Report of a task force of the Standing Committee for
International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum
Dis. 2006;65:1301–11.
4. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, British
Society for Rheumatology and British Health Professionals in
Rheumatology Standards, Guidelines and Audit Working Group
(SGAWG). British Society for Rheumatology and British Health
Professionals in Rheumatology guideline for the management of gout.
Rheumatol (Oxford). 2007;46:1372–4.
5. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Mae S, Neogi T, et al. 2012
American College of Rheumatology guidelines for management of gout.
Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.
Arthritis Care Res. 2012;64(10):1447–61.
6. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al.
EULAR evidence based recommendations for gout. Part II: Management.
Report of a task force of the EULAR Standing Committee for International
Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:
1312–24.
7. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative
treatment if informed appropriately: proof-of-concept observational study.
Ann Rheum Dis. 2013;72:826–30.
8. Pascual E, Sivera F. Why is gout so poorly managed? Ann Rheum Dis. 2007;
66:1269–70.
9. Roddy E, Zhang W, Doherty M. Concordance of the management of
chronic gout in a UK primary-care population with the EULAR gout
recommendations. Ann Rheum Dis. 2007;66:1311–5.
10. Annemans L, Spaepen E, Gaskin M, Bonnemarie M, Malier V, Gilbert T, et al.
Gout in the UK and Germany: prevalence, comorbidities and management
in general practice 2000–2005. Ann Rheum Dis. 2008;67:960–6.
11. Cottrell E, Crabtree V, Edwards J, Roddy E. Improvement in the
management of gout is vital and overdue: an audit from a UK primary care
medical practice. BMC Family Practice. 2013;14:170.
12. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician
adherence to quality indicators for the management of gout and
asymptomatic hyperuricaemia: results from the UK General Practice
Research Database (GPRD). Rheumatol (Oxford). 2005;44:1038–42.
13. Neogi T, Hunter DJ, Chaisson CE, Allensworth-Davies D, Zhang Y. Frequency
and predictors of inappropriate management of recurrent gout attacks in a
longitudinal study. J Rheumatol. 2006;33:104–9.
14. Wall GC, Koenigsfeld CF, Hegge KA, Bottenberg MM. Adherence to
treatment guidelines in two primary care populations with gout. Rheumatol
Int. 2010;30:749–53.
15. Pal B, Foxall M, Dysart T, Carey F, Whittaker M. How is gout managed in
primary care? A review of current practice and proposed guidelines. Clin
Rheumatol. 2000;19:21–5.
16. Reaves E, Arroll B. Management of gout in a South Auckland general
practice. J Prim Health Care. 2014;6(1):73–8.
17. Harrold LR, Andrade SE, Briesacher B, Raebel MA, Fouayzi H, Yood RA, et al.
The dynamics of chronic gout treatment: medication gaps and return to
therapy. Am J Med. 2010;123(1):54–9.
18. Reach G. Treatment adherence in patients with gout. Joint Bone Spine.
2011;78:456–9.
19. Harrold LR, Mazor KM, Velten S, Ockene IS, Yood R. Patients and providers
view gout differently: a qualitative study. Chronic Illness. 2010;6:263–71.
20. Lipworth W, Kerridge I, Brett B, Day R. How clinical and research failures
lead to suboptimal prescribing: the example of chronic gout. BMJ. 2011;343:
d7459.
21. Harrold LR, Mazor KM, Peterson D, Naz N, Firneno C, Yood RA. Patients’
knowledge and beliefs concerning gout and its treatment: a population
based study. BMC Musculoskeletal Disorders. 2012;13:180.
22. Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, et al. Gout: why
is this curable disease so seldom cured? Ann Rheum Dis. 2012;71:1765–70.
23. Li Q-H, Dai L, Li Z-X, Liu H-J, Zou C-J, Ou-Yang X, et al. Questionnaire survey
evaluating disease-related knowledge for 149 primary gout patients and
184 doctors in south China. Clin Rheumatol. 2013;32:1633–40.
24. Singh JA. Quality of life and quality of care for patients with gout. Curr
Rheumatol Rep. 2009;11(2):154–60.
25. Spencer K, Carr A, Doherty M. Patient and provider barriers to effective
management of gout in general practice: a qualitative study. Ann Rheum
Dis. 2012;71:1490–5.
26. Singh JA. The impact of gout on patient’s lives: a study of African-
American and Caucasian men and women with gout. Arthritis Res
Ther. 2014;16(3):R132.
27. Patton M. Qualitative evaluation and research methods. Beverly Hills: Sage;
1990.
28. Mishler EG. Research interviewing: context and narrative. Harvard: Harvard
University Press; 1991.
29. Ziebland S, McPherson A. Making sense of qualitative data analysis: an
introduction with illustrations from DIPEx (personal experiences of health
and illness). Medical Education. 2006;40(5):405–14.
Richardson et al. BMC Musculoskeletal Disorders  (2016) 17:249 Page 7 of 8
30. Pound P, Britten N, Morgan M, Yardley L, Pope C, Daker-White G, Campbell
R. Resisting medicines: a synthesis of qualitative studies of medicine taking.
Soc Sci Med. 2005;61(1):133–55.
31. Townsend A, Wyke S, Hunt K. Managing multiple morbidity in mid-life: a
qualitative study of attitudes to drug use. BMJ. 2003;327:837.
32. Dalbeth N, Petrie KJ, House M, Chong J, Leung W, Chequdi R, McQueent
FM, Taylor WJ. lllness perceptions in patients with gout and the relationship
with progression of musculoskeletal disability. Arthritis Care & Research.
2011;63(11):1605–12.
33. Robinson PC, Schumacher HR. A qualitative and quantitative analysis of the
characteristics of gout patient education resources. Clin Rheumatol.
2013;32:771–8.
34. McAdams MA, Maynard JW, Baer AN, Köttgen A, Clipp S, Coresh J, Gelber
AC. Reliability and sensitivity of the self-report of physician-diagnosed gout
in the campaign against cancer and heart disease and the atherosclerosis
risk in the community cohorts. J Rheumatol. 2011;38(1):135–41.
35. Rees F, Hui M, Doherty M. Optimizing current treatment of gout. Nat Rev
Rheumatol. 2014;10:271–83.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Richardson et al. BMC Musculoskeletal Disorders  (2016) 17:249 Page 8 of 8
